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Objective: Deregulation of PP2A and its regulatory subunits is a common event in
breast cancer. The cBioPortal for Cancer Genomics shows that PP2A is deregulated in
59.6% of basal breast tumours, providing a possible target for therapy. This study aims
to investigate the expression of the PP2A complex components in various breast cancer
cell lines and the effect of mTOR signalling suppression on breast cancer signature
genes including the PP2A inhibitory subunits CIP2A, SET, SETBP1 and ANP32A.
Methods: RNASeqV2 and clinical data were obtained from the Cancer Genome Atlas
to investigate the PP2A enzyme complex across different breast cancer subtypes. Ten
human breast cancer cell lines, representing the various subtypes of breast cancer, were
used. qRT-PCR was used to measure expression levels of the PP2A subunits. An
Affymetrix/Panomics panel was used to assay molecular classifiers and transcripts of
interest, in the presence or absence of the mTOR inhibitor, rapamycin and the PP2A
activator, FTY720. Immunofluorescence was used to measure pS6K activity and follow
the cellular distribution upon addition of FTY720.
Results: In silico analysis of datasets show that CIP2A is significantly upregulated in
the HER2+ patients and the TNBC subgroup. To support this, qRT-PCR data in our
study shows a higher expression of CIP2A in TNBC cell lines. In addition, the TNBC
cell lines are more sensitive to low doses of FTY720. Immunofluorescence shows that
addition of 5 µM FTY720 resulted in a shift of pS6K from the nuclei of MDA-MB-231
cells to a cytoplasmic localisation. Of interest, drug-induced mTOR suppression,
down-regulated the expression of CIP2A and SET by more than 1.5 fold in various
breast cancer cell lines.
Conclusion: The TNBC tumours show the greatest overexpression of CIP2A indicating
an association between CIP2A and the malignant phenotype of this subset. Decreased
expression of the PP2A inhibitory subunits, CIP2A and SET following suppression of
mTOR activity imply a restoration of PP2A activity in TNBC cell lines. Hence, subsets
of patients with suppressed PP2A activity would be eligible for treatment using
therapies which target the PI3K/Akt/mTOR pathway.
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